Jeanette Wood has joined EpiAxis Therapeutics as Scientific Advisor and Alternate Director.
Following an international career in senior leadership positions in big pharma and small biotech, Jeanette currently holds board and scientific advisory roles at various biotech and academic organisations. These include SwissVax, Swiss Rockets, Basilea, Tolremo, Queensland Emory Drug Discovery Initiative, Biomedical Translation Bridge and Maurice Wilkins Institute.
Her board experience includes the successful listing of Nuevolution AG on the Swedish stock exchange and its recent takeover offer from Amgen. Jeanette’s last full time position was as CSO for Genkyotex, a Geneva-based Biotech company focused on creating first-in-class inhibitors of NADPH oxidases (NOX) for the treatment of fibrotic disease. Prior to this Jeanette held a Vice President position as Head of Oncology – Small Molecule Drug Discovery at AstraZeneca, in addition to senior scientific leadership roles at Novartis, including member of the Oncology Research Management Team and the Research Management Committee.
EpiAxis Chair Dr David Fuller said: “We are delighted to welcome Jeanette to the EpiAxis Board. Her extensive experience in commercial pre-clinical development extends and complements our existing skill set as we progress our several assets towards our maiden IND filing and refine the data package for pharma partnering.”
Jeanette Wood added: “I am very excited to join Epiaxis as a scientific, drug discovery and strategic advisor to support them in their quest for novel drugs targeting epigenetic pathways that drive resistance to cancer therapies.
“The Epiaxis lead LSD1 program addresses resistance of cancer cells as well immune cells and has potential application to a broad spectrum of cancers that develop resistance to standard and emerging therapies. In addition to generating preclinical data to validate the concept of LSD1 as a target, Epiaxis has generated exciting clinical data with their EPI-PRIMED clinical trial.”